Identification and characterization of CRG-L2, a new marker for liver tumor development

Carrie R. Graveel, Sarah R. Harkins-Perry, Luis G. Acevedo, Peggy J. Farnham

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Liver cancer is very common worldwide and the rates of hepatocellular carcinoma (HCC) have increased by over 70% in the last 2 decades in the US. Late diagnosis, because of the lack of clinical symptoms, and decreased hepatic function, because of underlying hepatic disease, lead to the extremely high mortality rates associated with HCC. Clearly, the identification of markers that are expressed early in the development of HCC and that are easily detected in high-risk patients would aid in early diagnosis and increased survival. We present the cloning and characterization of a novel gene, CRG-L2 (Cancer related gene-Liver 2), which displays high expression in murine and human hepatocellular carcinomas. Using in situ hybridization, we show that CRG-L2 mRNA levels are increased early during the development of liver tumors in C3H/HeJ mice, and that in normal tissues CRG-L2 mRNA is restricted to the murine testis and human placenta. Its restricted expression in normal tissues and unique early upregulation during tumor development make CRG-L2 an excellent candidate as a new clinical marker of HCC.

Original languageEnglish (US)
Pages (from-to)1730-1736
Number of pages7
JournalOncogene
Volume22
Issue number11
DOIs
StatePublished - Mar 20 2003
Externally publishedYes

Fingerprint

Neoplasm Genes
Tumor Biomarkers
Hepatocellular Carcinoma
Liver
Messenger RNA
Inbred C3H Mouse
Delayed Diagnosis
Liver Neoplasms
Placenta
In Situ Hybridization
Testis
Organism Cloning
Early Diagnosis
Neoplasms
Up-Regulation
Biomarkers
Survival
Mortality
Genes

Keywords

  • Cancer testis antigen
  • Hepatocellular carcinoma
  • Olfactomedin domain
  • Rapid amplification of cDNA ends
  • Tumor marker

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Graveel, C. R., Harkins-Perry, S. R., Acevedo, L. G., & Farnham, P. J. (2003). Identification and characterization of CRG-L2, a new marker for liver tumor development. Oncogene, 22(11), 1730-1736. https://doi.org/10.1038/sj.onc.1206309

Identification and characterization of CRG-L2, a new marker for liver tumor development. / Graveel, Carrie R.; Harkins-Perry, Sarah R.; Acevedo, Luis G.; Farnham, Peggy J.

In: Oncogene, Vol. 22, No. 11, 20.03.2003, p. 1730-1736.

Research output: Contribution to journalArticle

Graveel, CR, Harkins-Perry, SR, Acevedo, LG & Farnham, PJ 2003, 'Identification and characterization of CRG-L2, a new marker for liver tumor development', Oncogene, vol. 22, no. 11, pp. 1730-1736. https://doi.org/10.1038/sj.onc.1206309
Graveel, Carrie R. ; Harkins-Perry, Sarah R. ; Acevedo, Luis G. ; Farnham, Peggy J. / Identification and characterization of CRG-L2, a new marker for liver tumor development. In: Oncogene. 2003 ; Vol. 22, No. 11. pp. 1730-1736.
@article{e715c7b2b6aa4d2bbc7d0635ad1f7224,
title = "Identification and characterization of CRG-L2, a new marker for liver tumor development",
abstract = "Liver cancer is very common worldwide and the rates of hepatocellular carcinoma (HCC) have increased by over 70{\%} in the last 2 decades in the US. Late diagnosis, because of the lack of clinical symptoms, and decreased hepatic function, because of underlying hepatic disease, lead to the extremely high mortality rates associated with HCC. Clearly, the identification of markers that are expressed early in the development of HCC and that are easily detected in high-risk patients would aid in early diagnosis and increased survival. We present the cloning and characterization of a novel gene, CRG-L2 (Cancer related gene-Liver 2), which displays high expression in murine and human hepatocellular carcinomas. Using in situ hybridization, we show that CRG-L2 mRNA levels are increased early during the development of liver tumors in C3H/HeJ mice, and that in normal tissues CRG-L2 mRNA is restricted to the murine testis and human placenta. Its restricted expression in normal tissues and unique early upregulation during tumor development make CRG-L2 an excellent candidate as a new clinical marker of HCC.",
keywords = "Cancer testis antigen, Hepatocellular carcinoma, Olfactomedin domain, Rapid amplification of cDNA ends, Tumor marker",
author = "Graveel, {Carrie R.} and Harkins-Perry, {Sarah R.} and Acevedo, {Luis G.} and Farnham, {Peggy J.}",
year = "2003",
month = "3",
day = "20",
doi = "10.1038/sj.onc.1206309",
language = "English (US)",
volume = "22",
pages = "1730--1736",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Identification and characterization of CRG-L2, a new marker for liver tumor development

AU - Graveel, Carrie R.

AU - Harkins-Perry, Sarah R.

AU - Acevedo, Luis G.

AU - Farnham, Peggy J.

PY - 2003/3/20

Y1 - 2003/3/20

N2 - Liver cancer is very common worldwide and the rates of hepatocellular carcinoma (HCC) have increased by over 70% in the last 2 decades in the US. Late diagnosis, because of the lack of clinical symptoms, and decreased hepatic function, because of underlying hepatic disease, lead to the extremely high mortality rates associated with HCC. Clearly, the identification of markers that are expressed early in the development of HCC and that are easily detected in high-risk patients would aid in early diagnosis and increased survival. We present the cloning and characterization of a novel gene, CRG-L2 (Cancer related gene-Liver 2), which displays high expression in murine and human hepatocellular carcinomas. Using in situ hybridization, we show that CRG-L2 mRNA levels are increased early during the development of liver tumors in C3H/HeJ mice, and that in normal tissues CRG-L2 mRNA is restricted to the murine testis and human placenta. Its restricted expression in normal tissues and unique early upregulation during tumor development make CRG-L2 an excellent candidate as a new clinical marker of HCC.

AB - Liver cancer is very common worldwide and the rates of hepatocellular carcinoma (HCC) have increased by over 70% in the last 2 decades in the US. Late diagnosis, because of the lack of clinical symptoms, and decreased hepatic function, because of underlying hepatic disease, lead to the extremely high mortality rates associated with HCC. Clearly, the identification of markers that are expressed early in the development of HCC and that are easily detected in high-risk patients would aid in early diagnosis and increased survival. We present the cloning and characterization of a novel gene, CRG-L2 (Cancer related gene-Liver 2), which displays high expression in murine and human hepatocellular carcinomas. Using in situ hybridization, we show that CRG-L2 mRNA levels are increased early during the development of liver tumors in C3H/HeJ mice, and that in normal tissues CRG-L2 mRNA is restricted to the murine testis and human placenta. Its restricted expression in normal tissues and unique early upregulation during tumor development make CRG-L2 an excellent candidate as a new clinical marker of HCC.

KW - Cancer testis antigen

KW - Hepatocellular carcinoma

KW - Olfactomedin domain

KW - Rapid amplification of cDNA ends

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=0037457020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037457020&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1206309

DO - 10.1038/sj.onc.1206309

M3 - Article

C2 - 12642876

AN - SCOPUS:0037457020

VL - 22

SP - 1730

EP - 1736

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 11

ER -